Overview

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine, each in combination with prednisone, for the treatment of autoimmune hepatitis (AIH).
Phase:
Phase 2
Details
Lead Sponsor:
Veloxis Pharmaceuticals
Treatments:
Azathioprine
Prednisone
Tacrolimus